公开(公告)号：US20240043390A1

公开(公告)日：2024-02-08

申请号：US18200265

申请日：2023-05-22

Applicant: The Regents of the University of California

Inventor： David A. Nathanson ,  Wilson X. Mai ,  Michael E. Jung ,  Peter M. Clark ,  Timothy F. Cloughesy ,  Gyudong Kim ,  Johathan Tsang ,  Lorenz Urner

IPC: C07D239/95 ,  A61P35/00 ,  A61K31/40 ,  A61K31/496 ,  A61K31/517 ,  A61K31/519 ,  A61K45/06 ,  C07D405/10 ,  C07D491/056 ,  G01N33/50 ,  G01N33/574

CPC classification number: C07D239/95 ,  A61P35/00 ,  A61K31/40 ,  A61K31/496 ,  A61K31/517 ,  A61K31/519 ,  A61K45/06 ,  C07D405/10 ,  C07D491/056 ,  G01N33/5011 ,  G01N33/57407

Abstract: The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.